PMID- 24142608
OWN - NLM
STAT- MEDLINE
DCOM- 20140430
LR  - 20131021
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 19
DP  - 2013 Oct
TI  - High-dose immunosuppressive therapy combined with cord blood infusion and 
      non-myeloablative peripheral blood stem cell transplantation for patients with 
      severe aplastic anemia.
PG  - 2613-8
LID - 5065 [pii]
AB  - OBJECTIVES: The aim of this study was to compare the clinical effective rates of 
      high-dose immunosuppressive therapy combined with cord blood infusion (IS + CBI) 
      and non-myeloablative peripheral blood stem cell transplantation (NSCT) for 
      severe aplastic anemia (SAA). PATIENTS AND METHODS: Human leukocyte antigen 
      (HLA)-mismatched patients received immunosuppressive therapy combined with IS + 
      CBI, whereas those with HLA matches received NSCT. Clinical effective rates, 
      hematopoietic recovery, and prevalence of complications were compared between the 
      two groups. RESULTS: No significant difference in total effective rate or 2 years 
      long-term survival was observed between the two groups. The total effective 
      treatment in the NSCT, IS + CBI group was 80%, 68.75%, and the 2 years long-term 
      survival rate in two groups was 2 years 76.66%, 68.75%, respectively. The median 
      times of WBC > 1.0x109/L in the NSCT group was faster than that of IS + CBI group 
      (13 vs 19 days) (p = 0.027). The median recovery times of PLT and Hb in the NSCT 
      group was significantly faster than that of IS + CBI group (19 vs 50 days) (p = 
      0.00), (27 vs 57 days) (p = 0.001). The SAA group and the very SAA (VSAA) group 
      did not show a significant difference in effective rate (76.74% vs 68.42%) (p = 
      0.490). In the NSCT group, two preparative regimens did not show a significant 
      difference in effect (70.59% vs 92.31%) (p = 0.141). CONCLUSIONS: IS + CBI is 
      applicable to HLA-mismatched patients with SAA. NSCT is the treatment of choice 
      for patients with HLA matching alleles. Both treatment methods are effective on 
      VSAA.
FAU - Yu, Z
AU  - Yu Z
AD  - Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, 
      China. jijisos@sina.com.
FAU - Zhou, F
AU  - Zhou F
FAU - -Fu Ge, L
AU  - -Fu Ge L
FAU - Liu, X-M
AU  - Liu XM
FAU - Fang, Y
AU  - Fang Y
FAU - Xie, L
AU  - Xie L
FAU - Kong, F-S
AU  - Kong FS
FAU - Song, N-X
AU  - Song NX
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anemia, Aplastic/*therapy
MH  - Child
MH  - Child, Preschool
MH  - *Cord Blood Stem Cell Transplantation
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Peripheral Blood Stem Cell Transplantation
EDAT- 2013/10/22 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/10/22 06:00
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 5065 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 Oct;17(19):2613-8.